It is important to highlight that a combination therapy, such as dimethyl fumarate (DMF) targeting metabolite deficiency [3] combined with an MST1 inhibitor, could potentially enhance the treatment of HCC and inhibit tumor metastasis. Here, MST1 is linked to neoplasm.